Mallinckrodt PLC (NYSE:MNK) has been given a consensus rating of “Hold” by the eighteen ratings firms that are presently covering the company, MarketBeat.com reports. Four analysts have rated the stock with a sell recommendation, nine have given a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $30.88.

MNK has been the topic of a number of research reports. B. Riley dropped their price target on Mallinckrodt to $21.00 and set a “neutral” rating on the stock in a research report on Monday, December 31st. Zacks Investment Research raised Mallinckrodt from a “hold” rating to a “strong-buy” rating and set a $21.00 price objective for the company in a report on Tuesday, January 8th. ValuEngine raised Mallinckrodt from a “sell” rating to a “hold” rating in a research note on Monday, February 4th. Mizuho increased their price target on Mallinckrodt to $26.00 and gave the company a “neutral” rating in a research note on Thursday, February 28th. Finally, Morgan Stanley set a $32.00 price target on Mallinckrodt and gave the company a “hold” rating in a research note on Thursday, February 28th.

Shares of Mallinckrodt stock traded down $0.90 on Tuesday, reaching $18.23. 2,152,548 shares of the company were exchanged, compared to its average volume of 1,323,644. The company has a current ratio of 1.51, a quick ratio of 1.17 and a debt-to-equity ratio of 2.10. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of 2.28, a PEG ratio of 0.19 and a beta of 2.29. Mallinckrodt has a 1-year low of $11.65 and a 1-year high of $36.65.

Mallinckrodt (NYSE:MNK) last announced its quarterly earnings results on Tuesday, February 26th. The company reported $2.18 earnings per share for the quarter, topping analysts’ consensus estimates of $1.98 by $0.20. The business had revenue of $834.90 million for the quarter, compared to analysts’ expectations of $681.45 million. Mallinckrodt had a positive return on equity of 11.14% and a negative net margin of 134.63%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm earned $2.01 EPS. Sell-side analysts predict that Mallinckrodt will post 8.2 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in MNK. QS Investors LLC lifted its holdings in shares of Mallinckrodt by 14.3% in the fourth quarter. QS Investors LLC now owns 4,000 shares of the company’s stock valued at $64,000 after purchasing an additional 500 shares in the last quarter. Sheaff Brock Investment Advisors LLC lifted its holdings in shares of Mallinckrodt by 4.6% in the fourth quarter. Sheaff Brock Investment Advisors LLC now owns 13,440 shares of the company’s stock valued at $212,000 after purchasing an additional 594 shares in the last quarter. Martingale Asset Management L P lifted its holdings in shares of Mallinckrodt by 0.8% in the fourth quarter. Martingale Asset Management L P now owns 76,053 shares of the company’s stock valued at $1,202,000 after purchasing an additional 597 shares in the last quarter. Retirement Systems of Alabama lifted its holdings in shares of Mallinckrodt by 0.6% in the first quarter. Retirement Systems of Alabama now owns 108,703 shares of the company’s stock valued at $2,363,000 after purchasing an additional 685 shares in the last quarter. Finally, Arizona State Retirement System lifted its holdings in shares of Mallinckrodt by 1.2% in the fourth quarter. Arizona State Retirement System now owns 59,797 shares of the company’s stock valued at $945,000 after purchasing an additional 714 shares in the last quarter.

About Mallinckrodt

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza.

Further Reading: How do buyers and sellers choose a strike price?

Analyst Recommendations for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.